Literature DB >> 25754610

Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive-like behaviour in the WAG/Rij rat model of absence epilepsy.

Rita Citraro1, Antonio Leo1, Pasquale De Fazio2, Giovambattista De Sarro1, Emilio Russo1.   

Abstract

BACKGROUND AND
PURPOSE: Two of the most relevant unmet needs in epilepsy are represented by the development of disease-modifying drugs able to affect epileptogenesis and/or the study of related neuropsychiatric comorbidities. No systematic study has investigated the effects of chronic treatment with antipsychotics or antidepressants on epileptogenesis. However, such drugs are known to influence seizure threshold. EXPERIMENTAL APPROACH: We evaluated the effects of an early long-term treatment (ELTT; 17 weeks), started before seizure onset (P45), with fluoxetine (selective 5-HT-reuptake inhibitor), duloxetine (dual-acting 5-HT-noradrenaline reuptake inhibitor), haloperidol (typical antipsychotic drug), risperidone and quetiapine (atypical antipsychotic drugs) on the development of absence seizures and comorbid depressive-like behaviour in the WAG/Rij rat model. Furthermore, we studied the effects of these drugs on established absence seizures in adult (6-month-old) rats after a chronic 7 weeks treatment. KEY
RESULTS: ELTT with all antipsychotics did not affect the development of seizures, whereas, both ELTT haloperidol (1 mg · kg(-1) day(-1)) and risperidone (0.5 mg · kg(-1) day(-1)) increased immobility time in the forced swimming test and increased absence seizures only in adult rats (7 weeks treatment). In contrast, both fluoxetine (30 mg · kg(-1) day(-1)) and duloxetine (10-30 mg · kg(-1) day(-1)) exhibited clear antiepileptogenic effects. Duloxetine decreased and fluoxetine increased absence seizures in adult rats. Duloxetine did not affect immobility time; fluoxetine 30 mg · kg(-1) day(-1) reduced immobility time while at 10 mg · kg(-1) day(-1) an increase was observed. CONCLUSIONS AND IMPLICATIONS: In this animal model, antipsychotics had no antiepileptogenic effects and might worsen depressive-like comorbidity, while antidepressants have potential antiepileptogenic effects even though they have limited effects on comorbid depressive-like behaviour.
© 2015 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25754610      PMCID: PMC4459032          DOI: 10.1111/bph.13121

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  97 in total

1.  International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy.

Authors:  Mike P Kerr; Seth Mensah; Frank Besag; Bertrand de Toffol; Alan Ettinger; Kousuke Kanemoto; Andres Kanner; Steven Kemp; Ennapadum Krishnamoorthy; W Curt LaFrance; Marco Mula; Bettina Schmitz; Ludgers Tebartz van Elst; Julian Trollor; Sarah J Wilson
Journal:  Epilepsia       Date:  2011-09-28       Impact factor: 5.864

2.  Linear pharmacokinetics of haloperidol in the rat.

Authors:  Y F Cheng; L K Paalzow
Journal:  Biopharm Drug Dispos       Date:  1992-01       Impact factor: 1.627

Review 3.  Animal models of neuropsychiatric disorders.

Authors:  Eric J Nestler; Steven E Hyman
Journal:  Nat Neurosci       Date:  2010-09-27       Impact factor: 24.884

Review 4.  Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy.

Authors:  Amy R Brooks-Kayal; Kevin G Bath; Anne T Berg; Aristea S Galanopoulou; Gregory L Holmes; Frances E Jensen; Andres M Kanner; Terence J O'Brien; Vicky H Whittemore; Melodie R Winawer; Manisha Patel; Helen E Scharfman
Journal:  Epilepsia       Date:  2013-08       Impact factor: 5.864

5.  Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity.

Authors:  Emilio Russo; Rita Citraro; Francesca Scicchitano; Agostina Urzino; Rosario Marra; Vincenzo Rispoli; Giovambattista De Sarro
Journal:  Behav Brain Res       Date:  2011-07-22       Impact factor: 3.332

Review 6.  The role of norepinephrine in epilepsy: from the bench to the bedside.

Authors:  Filippo S Giorgi; Chiara Pizzanelli; Francesca Biagioni; Luigi Murri; Francesco Fornai
Journal:  Neurosci Biobehav Rev       Date:  2004-09       Impact factor: 8.989

Review 7.  Should antidepressant drugs of the selective serotonin reuptake inhibitor family be tested as antiepileptic drugs?

Authors:  Hamada Hamid; Andres M Kanner
Journal:  Epilepsy Behav       Date:  2013-02-08       Impact factor: 2.937

8.  Reduced dopamine transporter binding in patients with juvenile myoclonic epilepsy.

Authors:  C Ciumas; T-B Robins Wahlin; A Jucaite; P Lindstrom; C Halldin; I Savic
Journal:  Neurology       Date:  2008-05-07       Impact factor: 9.910

9.  Spontaneous recurrent seizures in rats: amino acid and monoamine determination in the hippocampus.

Authors:  E A Cavalheiro; M J Fernandes; L Turski; M G Naffah-Mazzacoratti
Journal:  Epilepsia       Date:  1994 Jan-Feb       Impact factor: 5.864

10.  Childhood absence epilepsy: behavioral, cognitive, and linguistic comorbidities.

Authors:  Rochelle Caplan; Prabha Siddarth; Lesley Stahl; Erin Lanphier; Pamela Vona; Suresh Gurbani; Susan Koh; Raman Sankar; W Donald Shields
Journal:  Epilepsia       Date:  2008-06-13       Impact factor: 5.864

View more
  8 in total

1.  Fingolimod Exerts only Temporary Antiepileptogenic Effects but Longer-Lasting Positive Effects on Behavior in the WAG/Rij Rat Absence Epilepsy Model.

Authors:  Antonio Leo; Rita Citraro; Nicola Amodio; Caterina De Sarro; Maria Eugenia Gallo Cantafio; Andrew Constanti; Giovambattista De Sarro; Emilio Russo
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

2.  Microglial activation: an important process in the onset of epilepsy.

Authors:  Hu Zhao; Changgeng Zhu; Donghui Huang
Journal:  Am J Transl Res       Date:  2018-09-15       Impact factor: 4.060

3.  N-acetylcysteine aggravates seizures while improving depressive-like and cognitive impairment comorbidities in the WAG/Rij rat model of absence epilepsy.

Authors:  Martina Tallarico; Antonio Leo; Lorenza Guarnieri; Maria Caterina Zito; Carmen De Caro; Ferdinando Nicoletti; Emilio Russo; Andrew Constanti; Giovambattista De Sarro; Rita Citraro
Journal:  Mol Neurobiol       Date:  2022-02-15       Impact factor: 5.590

Review 4.  Serotonin and sudden unexpected death in epilepsy.

Authors:  Alexandra N Petrucci; Katelyn G Joyal; Benton S Purnell; Gordon F Buchanan
Journal:  Exp Neurol       Date:  2019-12-19       Impact factor: 5.330

5.  Absence seizures and their relationship to depression and anxiety: Evidence for bidirectionality.

Authors:  Benjamin F Gruenbaum; Mani Ratnesh S Sandhu; Raphael A O Bertasi; Tais G O Bertasi; Antonia Schonwald; Anirudh Kurup; Shaun E Gruenbaum; Isaac G Freedman; Melissa C Funaro; Hal Blumenfeld; Gerard Sanacora
Journal:  Epilepsia       Date:  2021-03-10       Impact factor: 6.740

6.  Role for serotonin2A (5-HT2A) and 2C (5-HT2C) receptors in experimental absence seizures.

Authors:  Marcello Venzi; François David; Joachim Bellet; Anna Cavaccini; Cristiano Bombardi; Vincenzo Crunelli; Giuseppe Di Giovanni
Journal:  Neuropharmacology       Date:  2016-04-13       Impact factor: 5.250

7.  Effects of Psychotropic Drugs on Seizure Threshold during Electroconvulsive Therapy.

Authors:  Su-Hyuk Chi; Hyun-Ghang Jeong; Suji Lee; So-Young Oh; Seung-Hyun Kim
Journal:  Psychiatry Investig       Date:  2017-09-11       Impact factor: 2.505

8.  Metabolic and Cognitive Effects of Ranolazine in Type 2 Diabetes Mellitus: Data from an in vivo Model.

Authors:  Velia Cassano; Antonio Leo; Martina Tallarico; Valentina Nesci; Antonio Cimellaro; Teresa Vanessa Fiorentino; Rita Citraro; Marta Letizia Hribal; Giovambattista De Sarro; Francesco Perticone; Giorgio Sesti; Emilio Russo; Angela Sciacqua
Journal:  Nutrients       Date:  2020-01-31       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.